Berenberg Bank started coverage on shares of UCB (OTCMKTS:UCBJF) in a note issued to investors on Wednesday, The Fly reports. The firm set a “buy” rating on the stock.
Other analysts also recently issued reports about the company. JPMorgan Chase & Co. upgraded UCB to a “buy” rating and set a $150.00 target price for the company in a research report on Thursday, September 2nd. Barclays cut UCB to a “hold” rating and set a $91.00 target price for the company. in a research note on Tuesday, October 19th. UBS Group upgraded UCB to a “buy” rating and set a $116.00 price target on the stock in a report on Monday, August 23rd. Finally, Jefferies Financial Group upgraded UCB to a “buy” rating and set a $130.00 price target on the stock in a report on Thursday, September 16th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $116.77.
OTCMKTS:UCBJF opened at $115.75 on Wednesday. UCB has a twelve month low of $93.00 and a twelve month high of $120.25. The stock’s 50 day moving average price is $114.13 and its two-hundred day moving average price is $106.99. The company has a quick ratio of 0.86, a current ratio of 1.23 and a debt-to-equity ratio of 0.26.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Featured Story: Return on Equity (ROE)
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.